Navigation Links
Increased Investments in New Drug Development Drives Demand for Cell-Based Assays, According to an Upcoming Report by Global Industry Analysts, Inc.
Date:7/17/2014

San Jose, California (PRWEB) July 17, 2014

Follow us on LinkedIn – GIA is pleased to announce the launch of a major research program analysing the trends impacting the market for “Cell-Based Assays”. Invited to participate in this comprehensive grassroots level global research initiative are senior industry executives, domain experts, technologists and market strategists. The new report to be issued shortly will offer accurate assessment of global market developments including major technologies, trends and challenges, together with descriptive, exploratory, and quantitative analysis of major product and geographic market segments. For details about how you can participate in this primary research program to include your inputs prior to the publication, please click here.

The drug discovery sector is the major end-user of cell-based assays. Characterized by versatility, cell-based assays represent a powerful research tool that provides valuable information for successful R&D. Cell-based assays also facilitate in studying biological characteristics of target drug compounds and their impact on cells/cellular systems in terms of activation of cell receptors, alteration in gene activity and expression of proteins. These assays are therefore emerging as a preferred tool for screening potential drug molecules. Cell-based assays also play an important role in toxicology testing in early stages of drug discovery, thereby reducing overall costs and the risk of clinical trial failures. Additionally, the market is being driven by the availability of high throughput screening (HTS) systems and advanced technological innovations such as development of label-free cell-based assays. Growing focus on expansion of drug portfolios and the ensuing increased investments in new drug development by pharma majors will generate lucrative opportunities for growth in the coming years.

The upcoming report will offer coverage on major companies including BD Biosciences, Beckman Coulter Inc., EMD Millipore, GE Healthcare Life Sciences, Life Technologies Corp, and Qiagen NV, among others.

In addition, the study will also provide:

  •     Valuable market based intelligence on new emerging trends, growth drivers, issues and challenges.
  •     Current coverage on company information and latest news and events including strategic corporate developments, and product innovations
  •     Fresh research perspectives, statistical findings, analyst analysis, and commentaries
  •     Accurate market estimates, projections, and forecasts across major market segments (Assay Kits (Functional Assays, Cell Death-Associated Assays, Cell Growth-Associated Assays) and Laboratory Automation) and geographic regions (the United States, Japan, Europe, and Rest of World).

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes 1500+ full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###

Read the full story at http://www.prweb.com/releases/cell_based_assays_market/healthcare_industry/prweb12026138.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Hospital-Diagnosed Maternal Infections Linked to Increased Autism Risk
2. New Genedata Expressionist for Mass Spectrometry Gains Increased Adoption in Metabolomics R&D
3. Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
4. SoundConnect Responds to Increased, Cost-Effective Unified Communications Demands Through Agent Partnership Program
5. Physician Familiarity With Biosimilars Has Increased Significantly Over The Past Year
6. High-flying pilots at increased risk of brain lesions
7. Pipette.com, Major Liquid Handling Distributor, Has Increased Their Bottletop Dispenser Stock
8. Kitware to Develop an In Situ Cosmology Analysis Framework for Increased Understanding of the Universe
9. SPIE Encouraged By Increased Science Funding in Obama Budget, Urges Applied Research Emphasis
10. Sigma-Aldrich Corporation Declares Increased Quarterly Dividend; Announces Live Webcasts Of Presentations At Two Upcoming Conferences
11. Bayer CropScience Announces LibertyLink LinkUp Offer Increased for 2013 Season
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... , Feb. 28, 2017  Phosphorus, a ... today the formation of the Phosphorus Scientific Advisory ... experts chosen to advise the company on the ... multi-site research initiatives. Please visit http://phosphorus.com/about-us/ ... initiatives. "We,ve gathered some of the ...
(Date:2/28/2017)... WuXi AppTec, a leading global pharmaceutical, ... platform company, today announced that its Lab Testing ... once again passed US FDA,s bioequivalence (BE) ... inspectors from FDA thoroughly audited WuXi,s quality system ... integrity, operation infrastructure, equipment, sample storage, archival system, ...
(Date:2/28/2017)... ... February 28, 2017 , ... ACEA Biosciences, a pioneer ... chronic diseases, has announced Dr. Roger (Feng) Luo as the new Vice President of ... a number of multinational drug companies, Dr. Luo will now team with Dr. Li ...
(Date:2/28/2017)... , Feb. 28, 2017 AMO Pharma Limited ... debilitating diseases including rare genetic diseases with limited or ... with the National Organization for Rare Diseases (NORD) and ... world in commemorating Rare Disease Day, the annual observance ... the millions of patients and families affected by rare ...
Breaking Biology Technology:
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent ... availability of a new report, Sensors for Robotics: Technologies, Markets ... ... ... IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine ...
(Date:1/25/2017)... The Elements of Enterprise Information Security ... of a comprehensive set of business processes and ... identities and providing a secured and documented access ... number of programs opted by enterprises to maintain ... processes and changing policies. However, there are some ...
Breaking Biology News(10 mins):